About Unicycive Therapeutics Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://unicycive.com/
Frequently Asked Questions
What is the 52-week range for UNCY?
The 52-week high is $8.74 and the 52-week low is $3.93.
What is the P/E ratio for UNCY?
The P/E ratio data is currently unavailable.
What is the dividend yield for UNCY?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -88.81%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -4159.11%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 4.11.
Analyst Recommendation Trends
Wall Street analyst consensus for UNCY over the last few months:
Latest UNCY News
Unicycive Therapeutics Appoints Meredith Manning to Board of Directors
MOUNTAIN VIEW, Calif., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced the appointment of Meredith Manning, M.B.A., to its Board of Directors. “We are very pleased to welcome Meredith to our Board of Directors. Her extensive commercialization experience, track record of building successful biopharmaceutical organizations, and
HC Wainwright & Co. Maintains Buy on Unicycive Therapeutics, Lowers Price Target to $13
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Unicycive Therapeutics (NASDAQ:UNCY) with a Buy and lowers the price target from $15 to $13.
Unicycive Therapeutics Announces Resubmission of New Drug Application for Oxylanthanum Carbonate
Resubmission of NDA includes Chemistry, Manufacturing, and Controls (CMC) data from a new drug product manufacturing vendor The resubmission package includes 12 months of OLC drug product stability data from the new manufacturing vendor Company anticipates FDA acceptance of the NDA within 30 days of resubmission; new assigned PDUFA date expected to be 6 months from resubmissionCurrent cash position allows runway into 2H 2027 MOUNTAIN VIEW, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Unicycive The
Unicycive Therapeutics Resubmits Its FDA New Drug Application For Oxylanthanum Carbonate For The Treatment Of Hyperphosphatemia In Patients With Chronic Kidney Disease On Dialysis; Expects PDUFA Date Six Months From Resubmission Date
The Company anticipates United States Food and Drug Administration (FDA) acceptance of the NDA within 30 days and a new assigned PDUFA date to be six months from the date of resubmission.The NDA resubmission includes
Unicycive Says Suit Alleges Securities Law Violations Over Statements On Oxylanthanum Carbonate FDA Application
https://www.sec.gov/ix?doc=/Archives/edgar/data/0001766140/000121390026104076/ea0306890-8k_unicycive.htm
Unicycive Therapeutics Discloses Securities Class Action Filed September 3 Against Company And Certain Officers
https://www.sec.gov/ix?doc=/Archives/edgar/data/0001766140/000121390026104076/ea0306890-8k_unicycive.htm
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-05-14 | Kenkare-Mitra Sara | +47,941 | - | - |
| 2026-05-14 | Laumas Sandeep | +47,941 | - | - |
| 2026-05-14 | Gupta Shalabh K. | +762,200 | - | - |
| 2026-05-14 | Kenkare-Mitra Sara | +42,100 | - | - |
| 2026-05-14 | Kenkare-Mitra Sara | +84,200 | - | - |
| 2026-05-14 | Gupta Pramod | +169,500 | - | - |
| 2026-05-14 | Jermasek Douglas | +169,500 | - | - |
| 2026-05-14 | Laumas Sandeep | +42,100 | - | - |
| 2026-05-14 | Laumas Sandeep | +84,200 | - | - |
| 2026-05-14 | Townsend John | +169,500 | - | - |
| 2026-05-14 | Jermasek Douglas | +169,500 | - | - |
| 2026-05-14 | Gupta Pramod | +169,500 | - | - |
| 2026-05-14 | Townsend John | +169,500 | - | - |
| 2026-05-14 | Gupta Shalabh K. | +762,200 | - | - |
| 2026-05-14 | Kenkare-Mitra Sara | +42,100 | - | - |
| 2026-05-14 | Kenkare-Mitra Sara | +84,200 | - | - |
| 2026-05-14 | Laumas Sandeep | +42,100 | - | - |
| 2026-05-14 | Laumas Sandeep | +84,200 | - | - |